Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever - Mire, Chad E; Cross, Robert W; Geisbert, Joan B; Borisevich, Viktoriya; Agans, Krystle N; Deer, Daniel J; Heinrich, Megan L; Rowland, Megan M; Goba, Augustine; Momoh, Mambu; Boisen, Mathew L; Grant, Donald S; et al. (Nature medicine, 2017)
Keywords: 13/1; 13/51; 631/326/596/1961; 692/699/255/2514; Animals; Antibodies; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - therapeutic use; Biomedicine; brief-communication; Cancer Research; Care and treatment; Cross Reactions; Drug dosages; Drug therapy; Enzyme-Linked Immunosorbent Assay; Fatalities; Fever; Glycoproteins; Health aspects; Humans; Immune Evasion - genetics; Immunohistochemistry; Immunology; Immunotherapy; Infectious Diseases; Lassa fever; Lassa Fever - prevention & control; Lassa virus - genetics; Macaca fascicularis; Medicine; Metabolic Diseases; Molecular Medicine; Monoclonal antibodies; Neurosciences; Plasma; Primates; Random Allocation; RNA, Viral - blood; Survival Rate; Vaccines; Viral diseases; Viral Load; Viruses